A Randomized Controlled Trial of Ebola Virus Disease Therapeutics

Mulangu, S., Dodd, L., Davey, R., et al. (2019). A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics. The New England Journal of Medicine. 381:2293-2303.
This article outlines the trial of four investigational Ebola therapies during an outbreak in the DRC in 2018. Patients received monoclonal antibody ZMapp (the control group), the antiviral agent remdesivir, the single monoclonal antibody MAb114, or the triple monoclonal antibody REGN-EB3. Of the 681 patients enrolled, results showed both MAb114 and REGN-EB3 reduced Ebola-related mortality.
Favorite:
You must Login to add a comment
  • This item doesn't have any comments

Enter your email address to receive important announcements and updates through the ASPR TRACIE Listserv.